Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 4
---
 accompanying notes to the condensed consolidated
financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025
and 1-for-20 reverse stock split effective June 13, 2025

2

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

(Unaudited)

    Convertible
    Preferred Stock  
    Series A  
    Additional  
    Stock 

    Total 

    Series A  
    Series B  
    Series C  
    Series D  
    Common Stock  
    Paid-in  
    Subscriptions 
     
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable 
     
    Deficit  
    Deficit 

    Balance
    at December 31, 2024 (Successor) 
     1,894  
    $1,708,396  
     273  
    $218,051  
     2,853  
    $1,249,999  
     -  
    $-  
     120,794  
    $12  
    $67,142,276  
    $(1,295,444) 
    $(70,917,853) 
    $(1,894,563)
  
    Issuance
    of shares of Series A Preferred Stock upon exercise of Series A Preferred Warrants 
     625  
     500,000  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (500,000) 
     500,000  
     -  
     500,000 
  
    Sale
    of common stock 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     15,000  
     2  
     587,998